Use of trans-[tetrachloridobis(1H-indazole)ruthenium sodium(III)] for the treatment of cancer
Combining trans-[tetrachloridobis(1H-indazole)ruthenium sodium(III) with ATRi inhibitors addresses treatment-resistant cancers by enhancing cell death pathways, effectively targeting BRAF-mutated colorectal cancer.
Patent Information
- Application Number
- JP2023529082
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-24
- Filing Date
- 2021-11-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-11-18
AI Technical Summary
Cancer, particularly colorectal cancer with BRAF mutations and microsatellite stability (MSS), is resistant to current treatments, necessitating new therapeutic approaches.
Combining trans-[tetrachloridobis(1H-indazole)ruthenium sodium(III) (BOLD-100) with ataxia telangiectasia mutation and Rad3-related protein kinase (ATRi) inhibitors to synergistically treat cancer, including BRAF-mutated colorectal cancer.
Enhances cancer cell death through caspase-8-dependent mechanisms and ROS-dependent ATR/CHK1 kinase activation, effectively treating resistant cancers like BRAF-mutated colorectal cancer.
Smart Images

Figure 0007948926000007 
Figure 0007948926000008 
Figure 0007948926000009
Abstract
Description
Technical Field
[0001] The present invention is in the field of therapeutic compounds comprising the combined use of trans-[tetrachloridobis(1H-indazole)ruthenate(III) sodium] and other therapeutic agents for treating cancer.
Background Art
[0002] Trans-[tetrachloridobis(1H-indazole)ruthenate(III) sodium] is a coordination complex of ruthenium with anticancer activity (also known as BOLD-100, KP1339, NKP-1339, IT-139, and Na[RuIIICl4(Hind)2]). Methods for preparing alkali metal salts of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] are described, for example, in PCT Patent Publication WO2018204930, and such compounds have Formula I:
Chemical Formula
Chemical Formula
[0003] ATR (ataxia telangiectasia mutation (ATM) and Rad3-related protein kinase) is a central component of the cellular DNA damage response (DDR). Single-stranded DNA coated with replication protein A (ssDNA) at DNA damage or stressed replication fork sites activates ATR, which in turn activates cell cycle checkpoints to suppress replication stress. Cancer cells are often characterized by features such as replication stress that lead to dependence on ATR checkpoint function. In this context, ATR inhibitors (ATRi) have shown promise as cancer treatments (International Publication 2017118734, U.S. Patent Application Publication 20190365745, International Publication 2016112374, International Publication 2017180723, International Publication 2018029117). Commercially available ATRi include AZD6783, M4344 (formerly VX-803), VE-821, M6620 (formerly VX-970, belzocertib, or VE-822), and BAY1895344 (Mei, L., Zhang, J., He, K. et al. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol 12, 43 (2019)). [Prior art documents] [Patent Documents]
[0004] [Patent Document 1] International Publication No. 2018204930 [Patent Document 2] International Publication No. 2017118734 [Patent Document 3] U.S. Patent Application Publication No. 20190365745 [Patent Document 4] International Publication No. 2016112374 [Patent Document 5] International Publication No. 2017180723 [Patent Document 6] International Publication No. 2018029117 [Non-patent literature]
[0005] [Non-Patent Document 1] Mei, L., Zhang, J., He, K. et al. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. JHematol Oncol 12,43(2019) [Overview of the Initiative] [Problems that the invention aims to solve]
[0006] A method and corresponding use are provided for treating cancer in patients requiring it, such as human patients, comprising administering an effective dose of trans-[tetrachloridobis(1H-indazole)ruthenium sodium(III)] (BOLD-100). BOLD-100 may be used in combination with an effective dose of ataxia telangiectasia mutation inhibitor and Rad3-related protein kinase (ATRi). An effective dose of BOLD-100 and an effective dose of ATRi may be synergistically effective in treating cancer, for example. The cancer may be resistant to treatment with BOLD-100 alone, or resistant to treatment with ATRi alone, or resistant to another chemotherapeutic agent or chemotherapy regimen, such as metastatic cancer. The cancer may be colorectal cancer (CRC), such as CRC adenocarcinoma. The cancer may be characterized by a BRAF mutation (BRAFMT). The cancer may further be characterized by microsatellite stability (MSS). Therefore, the selected embodiment involves monotherapy with BOLD-100 or combination therapy with BOLD-100 and ATRi in the treatment of MSS BRAFMT CRC, such as metastatic MSS BRAFMT CRC. In combination therapy, BOLD-100 and ATRi may be administered sequentially in any order, or in combination as a co-formulation or separately. [Brief explanation of the drawing]
[0007] [Figure 1] The figure includes two heatmaps, each with a consensus molecular subtype (CMS) profile along the X-axis, and the right-hand heatmap with pathway names (Hallmarks) along the Y-axis, indicating that endoplasmic reticulum protein response (UPR) and DNA repair are the major deregulated pathways in the CMS1 / BRAFMT subgroup with the worst outcomes. [Figure 2] The figure includes an upper panel with (A) a Western blot image and (B) three bar graphs, and a lower panel with two bar graphs (A and B), together showing that BRAFMT, MSS CRC cells are sensitive to treatment with BOLD-100. [Figure 3] The figure includes three panels: (A) a line graph above the blot image, (B) the blot image, and (C) the blot image and scatter plot, which together show that carcinogenic BRAF is a determinant of the response to BOLD-100 treatment. [Figure 4] The figure includes (A) two tables, (B) a scatter plot, (C) a blot image above a bar graph, and (D) two blot images adjacent to the two bar graphs, together showing that BOLD-100-induced cell death is caspase-8 dependent. [Figure 5] The figure includes (A) a heatmap and (B) two schematic diagrams, together showing that BOLD-100 treatment results in activation of the DNA damage repair pathway in BRAFMT CRCs. [Figure 6] The figure includes three panels: (A) two heatmaps and bar graphs, (B) two heatmaps and bar graphs, and (C) images of cell cultures and three bar graphs, together showing that ATR inhibition significantly increases the response to BOLD-100 treatment in BRAFMT CRC cells. [Figure 7]The figure includes three panels, each containing (A) two blot images, (B) two bar graphs, and (C) three bar graphs, together showing that the ATRi compounds AZD6738, M4344, and belzocertib increase cell death after BOLD-100 treatment in BRAFMT CRCs. [Figure 8] The figure includes four panels, each containing (A) two blot images, (B) two blot images, (C) two bar graphs, and (D) a blot image and a bar graph, together demonstrating that BOLD-100 induces ROS-dependent ATR / CHK1 kinase activation and cell death in BRAFMT CRC cells. [Figure 9] This bar graph shows that BOLD-100 is most effective in treating CMS1 and CMS4 CRC, which are difficult to treat with other therapies. [Figure 10] The figure includes two panels, (A) a bar graph for a corresponding scatter plot and (B) a scatter plot, showing that ATR inhibition significantly increases the response to BOLD-100 treatment in multiple myeloma. [Modes for carrying out the invention]
[0008] As disclosed herein, BOLD-100 has been shown to have a dramatic effect on the survival of BRAFMT CRC cells. Therefore, a therapy for treating BRAFMT CRC with BOLD-100 is provided. Furthermore, synergistic effects are disclosed in the treatment of cancer cells exemplified by BRAFMT CRC cells with BOLD-100 in combination with an inhibitor of ataxia telangiectasia mutation and Rad3-related protein kinase (ATRi). Therefore, a therapy for treating cancer including BRAFMT CRC is provided using BOLD-100 in combination with ATRi.
[0009] In vitro CellTitle-Glo® and Annexin V / PI sensitivity testing was performed using a panel of isogenic and heterogenic V600E BRAFMT and BRAFWT cells, showing that BRAFMT and MSS CRC cells showed an IC50 of 9.25–31 μM. 50 The cells showed high sensitivity to BOLD-100. Treatment with BOLD-100 resulted in an early decrease in GRP78 levels and an increase in the expression level of the endoplasmic reticulum stress protein CHOP. This was associated with caspase-8-dependent cell death in BRAFMT CRC cells. Notably, silencing CHOP did not suppress BOLD-100-induced cell death in BRAFMT CRC cells, indicating that the endoplasmic reticulum protein response (UPR) pathway did not play a role in cell death after BOLD-100. RNA sequencing and IPA bioinformatics analysis showed that cell cycle regulation and DNA repair were the most significant deregulation pathways after BOLD-100 treatment. Further mechanistic studies suggest that BOLD-100 induces caspase-8-dependent cell death in BRAFMT cells. T1989 pChk1 S345 It was also revealed that this induces a rapid and powerful increase in γH2AX expression levels.
[0010] The ATRi compounds AZD6783 and M4344, when combined with BOLD-100, induced strong synergistic effects and apoptosis, particularly in BRAFMT CRC cells. Notably, the ROS scavenger NAC was BOLD-100-inducible CHOP, pATR T1989 pChk1 S345 Furthermore, it suppressed γH2AX levels and rescued BRAFMT CRC cells from cell death after BOLD-100 treatment.
[0011] Further embodiments of the present invention provide a method for preparing a pharmaceutical product containing the sodium salt of trans-[tetrachlorobis(1H-indazole)rutheniumate(III)] (i.e., BOLD-100).
[0012] One aspect of the present invention provides a method for preparing a sterile lyophilized pharmaceutical product containing trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)]. This formulation is suitable for administration to patients. The formulation comprises trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], a pH buffer, and a cryoprotectant. A general method for providing the formulation includes the steps of preparing a buffer solution, preparing a cryoprotectant aqueous solution, dissolving trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] in the buffer solution, adding the cryoprotectant solution, sterile filtration (e.g., aseptic filtration), filling into vials under sterile conditions, and lyophilizing under sterile conditions. Suitable buffers include, but are not limited to, citrate, TRIS, acetate, EDTA, HEPES, tricine, and imidazole. The use of phosphate buffer is possible but undesirable. A preferred aspect of the present invention is the use of a citrate / sodium citrate buffer. Suitable cryoprotectants include, but are not limited to, sugars, monosaccharides, disaccharides, polyalcohols, mannitol, sorbitol, sucrose, trehalose, dextran, and dextrose. A preferred embodiment of the present invention is the use of mannitol as a cryoprotectant.
[0013] As described herein, trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] can decompose into compound A in water (Scheme II). Those skilled in the art will recognize that limiting this decomposition reaction is advantageous for obtaining the highest purity product. It has been found that cooling the trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] solution during the formulation process significantly reduces the amount of compound A present in the lyophilized product. In one aspect of the present invention, the trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] solution is cooled to 4°C during the formulation process. In another aspect of the present invention, the trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] solution is cooled to 2-8°C during the formulation process. In yet another aspect of the present invention, the trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] solution is cooled to 2-15°C during the formulation process.
[0014] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], a suitable buffer, and mannitol. In some embodiments, the suitable buffer comprises a citrate buffer. For example, in some embodiments, the citrate buffer comprises sodium citrate and citric acid.
[0015] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, and mannitol.
[0016] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, mannitol, and mer, trans-[RuIIICl3(Hind)2(H2O)].
[0017] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[RuIIICl3(Hind)2(H2O)], and a cesium salt.
[0018] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, and sodium mannitol, wherein trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is amorphous.
[0019] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, mannitol, and mer, trans[RuIIICl3(Hind)2(H2O)], wherein trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is amorphous.
[0020] One embodiment of the present invention provides a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans[RuIIICl3(Hind)2(H2O)], and a cesium salt, wherein trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is amorphous.
[0021] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans[RuIIICl3(Hind)2(H2O)] and a cesium salt, mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 to 0.4 weight percent of the composition. Provided is a composition, wherein cesium accounts for about 0.00001 to about 0.01 percent of the composition.
[0022] One embodiment of the present invention provides a composition comprising trans-[sodium tetrachlorobis(1H-indazole)ruthenate(III)], sodium citrate, citric acid, mannitol, mer,trans[Ru III Cl3(Hind)2(H2O)] and a cesium salt, wherein mer,trans-[Ru III Cl3(Hind)2(H2O)] accounts for about 0.01 to about 0.4 weight percent of the composition, and cesium accounts for about 0.00001 to about 0.01 weight percent of the composition.
[0023] One embodiment of the present invention provides a composition comprising trans-[sodium tetrachlorobis(1H-indazole)ruthenate(III)], sodium citrate, citric acid, mannitol, mer,trans[Ru III Cl3(Hind)2(H2O)] and a cesium salt, wherein mer,trans-[Ru III Cl3(Hind)2(H2O)] accounts for about 0.01 to about 0.2 weight percent of the composition, and cesium accounts for about 0.00001 to about 0.01 weight percent of the composition.
[0024] One embodiment of the present invention provides a composition comprising trans-[sodium tetrachlorobis(1H-indazole)ruthenate(III)], mer,trans[Ru III Cl3(Hind)2(H2O)] and a cesium salt, wherein mer,trans-[Ru III Cl3(Hind)2(H2O)] accounts for about 0.01 to about 0.40 weight percent of the composition, and cesium accounts for about 0.00001 to about 0.01 weight percent of the composition.
[0025] One embodiment of the present invention is trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, The composition is a freeze-dried powder, mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 to 0.40 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of about 0.00001 to about 0.01 weight percent of the composition.
[0026] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, The composition is a freeze-dried powder, mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 to 0.3 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of approximately 0.00001 to approximately 0.1 weight percent of the composition.
[0027] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 to 0.3 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of approximately 0.00001 to approximately 0.1 weight percent of the composition.
[0028] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, The composition is a freeze-dried powder, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 11.5 to 14.0 weight percent of the composition. Citric acid makes up approximately 43.9 to 53.7 percent by weight of the composition. Sodium citrate makes up about 25.7 to 23.1 percent by weight of the composition. Mannitol makes up about 11.5 to about 14.0 weight percent of the composition. mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 and approximately 0.3 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of approximately 0.00001 to approximately 0.1 weight percent of the composition.
[0029] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, The composition is a freeze-dried powder, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 10.2 to 15.3 weight percent of the composition. Citric acid makes up approximately 39.0 to 58.5% by weight of the composition. Sodium citrate makes up about 20.5 to about 30.8% by weight of the composition. Mannitol makes up about 10.2 to about 15.3% by weight of the composition. mer, Trans-[Ru IIICl3(Hind)2(H2O) is present in approximately 0.01 and approximately 0.3 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of approximately 0.00001 to approximately 0.1 weight percent of the composition.
[0030] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], sodium citrate, citric acid, mannitol, mer, trans-[Ru III A composition comprising Cl3(Hind)2(H2O) and a cesium salt, The composition is a freeze-dried powder, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 10.2 to 15.3 weight percent of the composition. mer, Trans-[Ru III Cl3(Hind)2(H2O) is present in approximately 0.01 and 0.3 weight percent of the composition. The present invention provides a composition in which cesium is present in an amount of approximately 0.00001 to approximately 0.1 weight percent of the composition.
[0031] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, and sodium citrate, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 49.86% by weight of the composition. Mannitol makes up approximately 49.86% by weight of the composition. Citric acid makes up about 0.187 weight percent of the composition. The present invention provides a composition in which sodium citrate is present at approximately 0.093% by weight of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0032] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, and sodium citrate, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 40 to 60 weight percent of the composition. Mannitol makes up about 40 to 60 percent by weight of the composition. Citric acid is present in an amount of approximately 0.01 to 0.5 weight percent of the composition. The present invention provides a composition in which sodium citrate is present at a weight percentage of about 0.001 to about 0.25 of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0033] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, and sodium citrate, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 30 to 70% by weight of the composition. Mannitol makes up about 30 to 70 percent by weight of the composition. Citric acid is present in an amount of approximately 0.001 to 1 weight percent of the composition. The present invention provides a composition in which sodium citrate is present at a concentration of about 0.0001 to about 1 weight percent of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0034] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and Ru III A composition containing Cl3(Hind)2(H2O), Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 49.86% by weight of the composition. Mannitol makes up approximately 49.86% by weight of the composition. Citric acid makes up about 0.187 weight percent of the composition. Sodium citrate is present at approximately 0.093% by weight of the composition. Ru III The present invention provides a composition in which Cl3(Hind)2(H2O) is present at a weight percentage of 0.5 or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0035] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and Ru III A composition containing Cl3(Hind)2(H2O), Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 40 to 60 weight percent of the composition. Mannitol makes up about 40 to 60 percent by weight of the composition. Citric acid is present in an amount of approximately 0.01 to 0.5 weight percent of the composition. Sodium citrate is present in a weight percentage of approximately 0.001 to approximately 0.25 of the composition. Ru III The present invention provides a composition in which Cl3(Hind)2(H2O) is present at a weight percentage of about 0 to about 0.5 of the composition. In some such embodiments, the composition is a lyophilized powder.
[0036] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III A composition containing Cl3(Hind)2(H2O) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 30 to 70% by weight of the composition. Mannitol makes up about 30 to 70 percent by weight of the composition. Citric acid is present in an amount of approximately 0.001 to approximately 1 weight percent of the composition. Sodium citrate is present in a composition of approximately 0.0001 to approximately 1 weight percent. Ru III Cl3(Hind)2(H2O) is present in a composition of 0.5% by weight or less. The present invention provides a composition in which cesium is 0.25% by weight or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0037] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 49.61% by weight of the composition. Mannitol makes up approximately 49.86% by weight of the composition. Citric acid makes up about 0.187 weight percent of the composition. Sodium citrate is present at approximately 0.093% by weight of the composition. The present invention provides a composition in which cesium is present at approximately 0.25% by weight of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0038] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 40 to 60 weight percent of the composition. Mannitol makes up about 40 to 60 percent by weight of the composition. Citric acid is present in an amount of approximately 0.01 to 0.5 weight percent of the composition. Sodium citrate is present in a weight percentage of approximately 0.001 to approximately 0.25 of the composition. The present invention provides a composition in which cesium is present at a weight percentage of about 0.1 to about 0.5 of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0039] One embodiment of the present invention is a composition comprising trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 30 to 70% by weight of the composition. Mannitol makes up about 30 to 70 percent by weight of the composition. Citric acid is present in an amount of approximately 0.001 to 1 weight percent of the composition. Sodium citrate is present in a composition of approximately 0.0001 to approximately 1 weight percent. The present invention provides a composition in which cesium is present at a concentration of about 0.01 to about 1 weight percent of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0040] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN), Ru III A composition containing Cl3(Hind)(HN=C(Me)ind) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 46.61% by weight of the composition. Mannitol makes up approximately 49.86% by weight of the composition. Citric acid makes up about 0.187 weight percent of the composition. Sodium citrate is present at approximately 0.093% by weight of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a weight percentage of 1.25% or less of the composition. Ru III Cl3(Hind)(HN=C(Me)ind) is 1.0 weight percent or less of the composition. The present invention provides a composition in which cesium is present at a concentration of 0.25% by weight or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0041] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN), Ru III A composition containing Cl3(Hind)(HN=C(Me)ind) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is among approximately 46.61% by weight of the composition. Mannitol makes up approximately 49.86% by weight of the composition. Citric acid makes up about 0.187 weight percent of the composition. Sodium citrate is present at approximately 0.093% by weight of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a weight percentage of 1.25% or less of the composition. Ru III Cl3(Hind)(HN=C(Me)ind) is 1.0 weight percent or less of the composition. The present invention provides a composition in which cesium is present at a concentration of 0.25% by weight or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0042] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN), Ru III A composition containing Cl3(Hind)(HN=C(Me)ind) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 40 to 60 weight percent of the composition. Mannitol makes up about 40 to 60 percent by weight of the composition. Citric acid is present in an amount of approximately 0.01 to 0.5 weight percent of the composition. Sodium citrate is present in a weight percentage of approximately 0.001 to approximately 0.25 of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present at a weight of approximately 1.0% or less of the composition. The present invention provides a composition in which cesium is present at a concentration of 0.25 percent or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0043] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN), Ru III A composition containing Cl3(Hind)(HN=C(Me)ind) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] constitutes approximately 30 to 70% by weight of the composition. Mannitol makes up about 30 to 70 percent by weight of the composition. Citric acid is present in an amount of approximately 0.001 to 1 weight percent of the composition. Sodium citrate is present in a composition of approximately 0.0001 to approximately 1 weight percent. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present at a weight of approximately 1.0% or less of the composition. The present invention provides a composition in which cesium is present at a concentration of 0.25 percent or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0044] One embodiment of the present invention comprises trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN), Ru III A composition containing Cl3(Hind)(HN=C(Me)ind) and cesium, Trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)] is present in approximately 20 to 80 weight percent of the composition. Mannitol makes up about 20 to 80 percent by weight of the composition. Citric acid is present in an amount of approximately 0.0001 to 5 weight percent of the composition. Sodium citrate is present in the composition at a weight percentage of approximately 0.00001 to approximately 5.00001. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present at a weight of approximately 1.0% or less of the composition. The present invention provides a composition in which cesium is present at a concentration of 0.25 percent or less of the composition. In some such embodiments, the composition is a freeze-dried powder.
[0045] In some embodiments, the present invention provides unit dosage forms comprising the formulations or compositions described herein. As used herein, the term “unit dosage form” refers to a physically distinct unit of the formulation provided that is appropriate for the subject being treated. However, it will be understood that the total daily dose of the formulation provided is to be determined by the attending physician within the bounds of sound medical judgment. The specific effective dose level for any particular subject or organism will depend on a variety of factors, including the disorder being treated and its severity; the activity of the particular activator used; the particular formulation used; the subject’s age, weight, overall health, sex, and diet; the timing and rate of administration of the particular activator used; the duration of treatment; the drugs and / or additional therapies used in combination with or concurrently with the particular (one or more) compounds used, as well as similar factors well known in the medical field.
[0046] The compositions of the present invention can be provided as unit dosage forms. In some embodiments, the unit dosage form is a vial containing trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, and sodium citrate.
[0047] In some embodiments, the present invention provides a vial containing trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, and cesium as the unit dosage form.
[0048] In some embodiments, the present invention includes trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, sodium citrate, Ru III Cl3(Hind)2(H2O), RuIII Cl3(Hind)2(CH3CN), Ru III The unit dosage form is a vial containing Cl3(Hind)(HN=C(Me)ind) and cesium.
[0049] The present invention further encompasses pharmaceutical packs and / or kits containing the compositions described herein, or unit dosage forms containing the provided compositions, and containers (e.g., foil or plastic packaging, or other suitable containers). Instructions for use may further be provided with such kits.
[0050] In some embodiments, the present invention can be provided as a unit dosage form. In fact, a vial containing trans-[tetrachlorobis(1H-indazole)ruthenate sodium(III)], mannitol, citric acid, and sodium citrate is a unit dosage form as shown in Table 3. [Table 1] In some embodiments, the pharmaceutical ingredients listed in Table 3 further contain cesium, Cesium content is 0.25% by weight or less of the composition.
[0051] In some embodiments, the pharmaceutical ingredients listed in Table 3 are cesium, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN) and Ru III It further includes Cl3(Hind)(HN=C(Me)ind), Cesium is present at a concentration of approximately 0.25% by weight or less of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present in a composition of approximately 1.0 weight percent or less.
[0052] In some embodiments, the pharmaceutical composition is selected from those listed in Table 4: [Table 2] In some embodiments, the pharmaceutical ingredients listed in Table 4 further contain cesium, Cesium content is 0.25% by weight or less of the composition.
[0053] In some embodiments, the pharmaceutical ingredients listed in Table 4 are cesium, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN) and Ru III It further includes Cl3(Hind)(HN=C(Me)ind), Cesium is present at a concentration of approximately 0.25% by weight or less of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present in a composition of approximately 1.0 weight percent or less.
[0054] In some embodiments, the present invention can be provided as a unit dosage form. Indeed, a vial containing trans-[tetrachlorobis(1H-indazole)rutheniumate sodium(III)], mannitol, citric acid, and sodium citrate is a unit dosage form as shown in Table 5: [Table 3] In some embodiments, the pharmaceutical ingredients listed in Table 5 further contain cesium, Cesium content is 0.25% by weight or less of the composition.
[0055] In some embodiments, the pharmaceutical ingredients listed in Table 5 are cesium, RuIII Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN) and Ru III It further includes Cl3(Hind)(HN=C(Me)ind), Cesium is present at a concentration of approximately 0.25% by weight or less of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present in a composition of approximately 1.0 weight percent or less.
[0056] In some embodiments, the pharmaceutical composition is selected from those listed in Table 6: [Table 4] In some embodiments, the pharmaceutical ingredients listed in Table 6 further contain cesium, Cesium content is 0.25% by weight or less of the composition.
[0057] In some embodiments, the pharmaceutical ingredients listed in Table 6 are cesium, Ru III Cl3(Hind)2(H2O), Ru III Cl3(Hind)2(CH3CN) and Ru III It further includes Cl3(Hind)(HN=C(Me)ind), Cesium is present at a concentration of approximately 0.25% by weight or less of the composition. Ru III Cl3(Hind)2(H2O) is present in a composition of approximately 0.5% by weight or less. Ru III Cl3(Hind)2(CH3CN) is present in a composition of approximately 1.25% by weight or less. Ru III Cl3(Hind)(HN=C(Me)ind) is present in a composition of approximately 1.0 weight percent or less.
[0058] In some embodiments, the pharmaceutical components are as described in any of Tables 3 to 6, and further include cesium. In some embodiments, the cesium is present in amounts of approximately 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.040, 0.045, 0.050, 0.055, 0.060, 0.0 It exists in amounts of 65, 0.070, 0.075, 0.080, 0.085, 0.090, 0.095, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, or 1.0 weight percentage.
[0059] In some embodiments, the present invention provides a method for treating cancer in a subject requiring it, comprising administering an effective amount of BOLD-100 to the subject. In some embodiments, the subject is a human patient. In some embodiments, the cancer is colorectal cancer (CRC), which may be characterized by a BRAF mutation (BRAFMT) and further characterized by microsatellite stability (MSS). In some embodiments, BOLD-100 may be used in combination with chemotherapeutic agents such as immunotumor agents, e.g., inhibitors of telangiectatic ataxia mutations and Rad3-related protein kinase (ATRi).
[0060] In some embodiments, an effective amount of BOLD-100, either alone or in combination, for example in combination with ATRi, may be effective in reducing the amount of GRP78 in cancer cells after administration of BOLD-100.
[0061] According to one embodiment of the present invention, a method for treating cancer in a patient who requires it, 1) The step of administering a chemotherapy agent (such as ATRi) to the patient, 2) Next, the step of administering BOLD-100 or a pharmaceutically acceptable composition thereof to the patient, 3) A method is provided which includes the optional step of repeating steps 1 and 2.
[0062] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered one day after the chemotherapy agent (such as ATRi). In other embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered to the patient one week after the chemotherapy agent (such as ATRi). In yet another embodiment, BOLD-100 is administered to the patient one to seven days after the chemotherapy agent (such as ATRi).
[0063] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered simultaneously with a chemotherapeutic agent (such as ATRi). In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof and the chemotherapeutic agent (such as ATRi) are administered within approximately 20 to 28 hours of each other, or within approximately 22 to 26 hours of each other, or within approximately 24 hours of each other.
[0064] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered before a chemotherapeutic agent (such as ATRi). In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 8 to 16 hours before a chemotherapeutic agent (such as ATRi), or at least about 10 to 14 hours before a chemotherapeutic agent (e.g., ATRi), or at least about 12 hours before a chemotherapeutic agent (e.g., ATRi).
[0065] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 20 to 28 hours before a chemotherapeutic agent (such as ATRi), or at least about 22 to 26 hours before a chemotherapeutic agent (such as ATRi), or at least about 24 hours before a chemotherapeutic agent (such as ATRi).
[0066] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 44 to 52 hours before a chemotherapeutic agent (such as ATRi), or at least about 46 to 50 hours before a chemotherapeutic agent (such as ATRi), or at least about 48 hours before a chemotherapeutic agent (such as ATRi).
[0067] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 64 to 80 hours before a chemotherapeutic agent (such as ATRi), at least about 70 to 74 hours before a chemotherapeutic agent (such as ATRi), or at least about 72 hours before a chemotherapeutic agent (such as ATRi).
[0068] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered before the chemotherapeutic agent (such as ATRi). In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 8 to 16 hours after the chemotherapeutic agent (such as ATRi), or at least about 10 to 14 hours after the chemotherapeutic agent (such as ATRi), or at least about 12 hours after the chemotherapeutic agent (such as ATRi).
[0069] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 20 to 28 hours after a chemotherapeutic agent (such as ATRi), or at least about 22 to 26 hours after a chemotherapeutic agent (such as ATRi), or at least about 24 hours after a chemotherapeutic agent (such as ATRi).
[0070] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 44 to 52 hours after a chemotherapeutic agent (such as ATRi), or at least about 46 to 50 hours after a chemotherapeutic agent (such as ATRi), or at least about 48 hours after a chemotherapeutic agent (such as ATRi).
[0071] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 64 to 80 hours after a chemotherapeutic agent (such as ATRi), at least about 70 to 74 hours after a chemotherapeutic agent (such as ATRi), or at least about 72 hours after a chemotherapeutic agent (such as ATRi).
[0072] In certain embodiments, including BRAFMT CRC patients (such as patients with metastatic disease), the chemotherapy regimen may involve the use of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX); or 5-fluorouracil, leucovorin and irinotecan (FOLFIRI); or capecitabine + oxaliplatin; or 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI+bev) in combination with bevacizumab.
[0073] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered simultaneously with ATRi. In certain embodiments, when BOLD-100 or a pharmaceutically acceptable composition thereof and ATRi are administered in combination, the two therapeutic agents may be administered within approximately 20 to 28 hours of each other, or within approximately 22 to 26 hours of each other, or within approximately 24 hours of each other.
[0074] In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered before ATRi. In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 8 to 16 hours before ATRi, or at least about 10 to 14 hours before ATRi, or at least about 12 hours before ATRi. In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 20 to 28 hours before ATRi, or at least about 22 to 26 hours before ATRi, or at least about 24 hours before ATRi. In certain embodiments, BOLD-100 or a pharmaceutically acceptable composition thereof is administered at least about 44 to 52 hours before ATRi, or at least about 46 to 50 hours before ATRi, or at least about 48 hours before ATRi.
[0075] Titrable dosages can be adapted, for example, to allow a patient to take a smaller dose of medication than the unit dose, where "unit dose" is defined as the maximum dose of medication that can be taken at any given time or within a specific period of medication. Since not all patients require the same dose to achieve the same benefit, dose titration allows for a gradual increase in dose until different patients feel the medication is effective. Individuals with a larger build or faster metabolism may require a larger dose to achieve the same effect as those with a smaller build or slower metabolism. Therefore, titrable dosages offer advantages over standard forms of medication.
[0076] In selected embodiments, the formulation may be adapted to be delivered targeting one or more of the following: sublingual, buccal, oral, rectal, nasal, parenteral, and pulmonary systems. The formulation may be, for example, one or more of the following forms: gel, gel spray, tablet, liquid, capsule, injection, or vaporization.
[0077] Using conventional pharmaceutical practices, formulations or compositions suitable for administering the formulation to a subject can be provided. Routes of administration may include, for example, parenteral, intravenous, intradermal, subcutaneous, intramuscular, intracranial, orbital, intraocular, intraventricular, intrasacral, intraspinal, intrathecal, intrasacral, intraperitoneal, intranasal, inhalation, aerosol, topical, sublingual, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; for intranasal formulations, formulations may be in the form of powders, nasal drops or aerosols; and for sublingual formulations, formulations may be in the form of drops, aerosols or tablets.
[0078] Well-known methods in the art for preparing formulations can be found, for example, in "Remington: The Science and Practice of Pharmacy" (21st edition), ed. David Troy, 2006, Lippincott Williams & Wilkins. Formulations for parenteral administration may contain, for example, excipients, sterile water or saline, polyalkylene glycols such as polyethylene glycol, plant-derived oils, or hydrogenated naphthalene. The release of the compound can be controlled using biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholic acid, and deoxycholic acid, or may be oily solutions for administration in the form of nasal drops or gels.
[0079] The pharmaceutical composition of the present invention may be in any form that allows the composition to be administered to a patient. For example, the composition may be in the form of a solid, liquid, or gas (aerosol). The pharmaceutical composition of the present invention is formulated such that the active ingredient contained therein is bioavailable when the composition is administered to a patient. The composition administered to the patient may take the form of one or more dosing units; for example, a tablet, capsule, or cachet may be a single dosing unit, and a container of a compound in aerosol form may hold multiple dosing units.
[0080] The materials used in the preparation of a pharmaceutical composition should be pharmaceutically pure and nontoxic in the amounts used. The compositions of the present invention may contain one or more compounds (active ingredients) for which particularly desirable effects are known. It will be apparent to those skilled in the art that the optimal dosage of one or more active ingredients in a pharmaceutical composition depends on various factors. These factors include, but are not limited to, the type of subject (e.g., human), the specific form of the active ingredient, the mode of administration, and the composition used.
[0081] Generally, a pharmaceutical composition comprises a formulation of the present invention as described herein, mixed with one or more carriers. The carriers (one or more) may be particulate, such that the composition is in the form of, for example, a tablet or a powder. The carriers (one or more) may be liquids, and the composition may be, for example, an oral syrup or an injectable liquid. In addition, the carriers (one or more) may be gases, for example, to provide an aerosol composition useful for inhalation administration.
[0082] When intended for oral administration, the composition is preferably in either solid or liquid form, and semi-solid, semi-liquid, suspension, and gel forms are included herein as either solid or liquid forms.
[0083] As a solid formulation for oral administration, the composition can be formulated in the form of powder, granules, compressed tablets, pills, capsules, cachets, chewing gum, wafers, lozenges, and the like. Such solid compositions typically contain one or more inert diluents or food carriers. In addition, the following adjuvants may be present: binders such as syrup, acacia, sorbitol, polyvinylpyrrolidone, carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, tragacanth gum or gelatin, and mixtures thereof; excipients such as starch, lactose or dextrin; disintegrants such as alginic acid, sodium alginate, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotex; fillers such as lactose, mannitol, starch, calcium phosphate, sorbitol, methylcellulose, and mixtures thereof; lubricants such as magnesium stearate, high molecular weight polymers such as polyethylene glycol, high molecular weight fatty acids such as stearic acid, wetting agents such as silica or sodium lauryl sulfate, fluidizing agents such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; flavorings such as peppermint, methyl salicylate or orange flavor; colorants; and one or more of the following colorants may be present. If the composition is in the form of a capsule, for example a gelatin capsule, the composition may contain a liquid carrier such as polyethylene glycol or fatty oil in addition to the materials of the types described above.
[0084] The formulation may be in the form of a liquid, such as an elixir, syrup, solution, aqueous or oily emulsion or suspension, or a dry powder that can be reconstituted with water and / or other liquid media before use. The liquid may, as two examples, be for oral administration or for delivery by injection. For oral administration, a preferred composition contains, in addition to the compound of the present invention, one or more of the following: sweeteners, thickeners, preservatives (e.g., p-hydroxybenzoate alkyl), dyes / colorants, and flavor enhancers (flavoring agents). Compositions intended for administration by injection may contain one or more of the following: surfactants, preservatives (e.g., p-hydroxybenzoate alkyl), humectants, dispersants, suspending agents (e.g., sorbitol, glucose, or other sugar syrups), buffers, stabilizers, and isotonic agents. The emulsifier may be selected from lecithin or sorbitol monooleate.
[0085] The liquid pharmaceutical formulations of the present invention, whether they are solutions, suspensions or other similar forms, may contain one or more of the following adjuvants: sterile diluents such as water for injection, physiological saline, preferably physiological saline, Ringer's solution, or isotonic sodium chloride; fixing oils such as synthetic monoglycerides or diglycerides that can function as solvents or suspension media; polyethylene glycol, glycerin, propylene glycol, or other solvents; antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffering agents such as acetates, citrates, or phosphates; and agents for adjusting isotonicity such as sodium chloride or dextrose. Parenteral formulations can be sealed in glass or plastic ampoules, disposable syringes, or multi-dose vials. Physiological saline is a preferred adjuvant. The injectable pharmaceutical composition is preferably sterile.
[0086] Pharmaceutical formulations may be intended for topical administration, in which case the carrier may preferably comprise a solution, emulsion, ointment, cream, or gel base. The base may comprise, for example, one or more diluents such as petrolatum, lanolin, polyethylene glycol, beeswax, mineral oil, water, and alcohol, as well as emulsifiers and stabilizers. Thickeners may be present in the pharmaceutical composition for topical administration. When intended for transdermal administration, the composition may comprise a transdermal patch or an iontophoresis device.
[0087] The formulation may be intended for rectal administration, for example, in the form of a suppository that melts in the rectum to release the drug. Compositions for rectal administration may contain an oily base as a suitable non-irritating excipient. Such bases include, but are not limited to, lanolin, cocoa butter, and polyethylene glycol. Low-melting-point waxes are preferred for the preparation of suppositories, where a mixture of fatty acid glycerides and / or cocoa butter is a suitable wax. The aminocyclohexyl ether compound may be uniformly dispersed therein by melting and stirring the wax. The molten, homogeneous mixture is then poured into a mold of a suitable size and cooled to solidify.
[0088] The formulation may contain various materials that modify the physical form of the solid or liquid dosing unit. For example, the composition may contain a material that forms a coating shell around the active ingredient. The material forming the coating shell is typically inert and can be selected from, for example, sugars, shellac, and other enteric coating agents. Alternatively, the active ingredient may be encapsulated in a gelatin capsule or cachet.
[0089] Pharmaceutical formulations may consist of gaseous dosing units, for example, in the form of aerosols. The term aerosol is used to describe a variety of systems, ranging from colloidal to systems consisting of pressurized packages. Delivery may be by liquefied gas or compressed gas, or by a suitable pump system for dispensing the active ingredient. Aerosols of the compounds of the present invention may be delivered in single-phase, two-phase, or three-phase systems to deliver (one or more) active ingredients. Delivery of the aerosol may include necessary containers, activators, valves, sub-containers, etc., which together may form a kit.
[0090] Some biologically active compounds may be in the form of free bases or pharmaceutically acceptable salts, such as hydrochlorides, sulfates, phosphates, citrates, fumarates, methanesulfonates, acetates, tartrates, maleates, lactates, mandelates, salicylates, succinates, and other salts known in the art. A suitable salt would be selected to enhance the bioavailability or stability of the compound for a suitable mode of use (e.g., oral or parenteral administration).
[0091] The present invention also provides a kit for containing a pharmaceutical formulation along with instructions for use of the formulation. Preferably, the commercially available package contains one or more unit doses of the formulation. Formulations sensitive to light and / or air may require special packaging and / or formulation. For example, packaging that is opaque to light and / or sealed from contact with ambient air and / or formulated with a suitable coating or excipient may be used.
[0092] The formulations of the present invention can be provided alone or in combination with other compounds (e.g., small molecules, nucleic acid molecules, peptides, or peptide analogs) in the presence of a carrier or any pharmaceutically or bioacceptably permissible carrier. As used herein, “pharmaceutically acceptable carrier” or “excipient” includes any physiologically compatible solvent, dispersion medium, coating, antimicrobial and antifungal agents, isotonic agents, and absorption retarders. The carrier may be suitable for any appropriate dosage form. Pharmaceutically acceptable carriers generally include sterile aqueous solutions or dispersions and sterile powders. Supplementary active compounds may also be incorporated into the formulations.
[0093] The “effective dose” of a formulation according to the present invention includes a therapeutic effective dose or a prophylactic effective dose. The “therapeutic effective dose” refers to the amount effective in the required dosage and duration to achieve the desired therapeutic outcome. The therapeutic effective dose of a formulation may vary depending on factors such as the individual’s disease state, age, sex, and weight, as well as the compound’s ability to induce the desired response in the individual. The dosage regimen may be adjusted to provide the optimal therapeutic response. The therapeutic effective dose may also be the amount in which the therapeutically beneficial effects outweigh any toxic or adverse effects of the formulation or active compound. The “prophylactic effective dose” refers to the amount effective in the required dosage and duration to achieve the desired prophylactic outcome. Typically, a prophylactic dose is administered to a subject before or in the early stages of the disease, such that the prophylactic effective dose may be less than the therapeutic effective dose. For any particular subject, the timing and dosage of treatment may be adjusted over time (for example, the timing may be daily, every other day, weekly, or monthly) according to the individual’s needs and the professional judgment of the person administering or supervising the administration of the composition.
[0094] In therapeutic applications, synergistic effects between active ingredients occur when the observed combined therapeutic effect is greater than the sum of the therapeutic effects of the individual active ingredients, or when a new therapeutic effect is produced that the active ingredients alone could not produce. Therefore, when the components of a formulation are present in synergistically effective amounts, the formulation will produce a greater therapeutic effect than that achieved by the individual active ingredients administered alone at equivalent doses. In this regard, the enhancement of therapeutic effect may take the form of increased efficacy or potency and / or a reduction in adverse effects. Synergistic effects may be mediated whole or partially by the pharmacokinetics and / or pharmacodynamics of the active ingredients in the subject, and as a result, the amount and proportion of components in the formulation may be synergistic in vivo. This in vivo synergy can be performed using a formulation containing active ingredients in amounts and proportions that are also synergistic in in vitro efficacy assays. Therefore, as used herein, the term “synergistically effective amount” refers to an amount that is synergistic in vivo and / or in vitro. The numerical quantification of synergistic effects is often expressed as a partial inhibitory concentration index (FICI), which represents the sum of the partial inhibitory concentrations (FICs) of each drug tested. The FIC is determined for each drug by dividing the minimum inhibitory concentration (MIC, the lowest concentration of a drug that prevents visible bacterial growth in a standard in vitro assay—a standard colorimetric assay based on resazurin) of each drug when used alone. In very general terms, an FICI lower or higher than 1 indicates positively correlated activity (at least additive synergy) or a lack of positive interaction, respectively. More precisely, the synergy of two compounds can be conservatively defined as an FICI of ≤0.5 (see Odds, 2003; with additivity or additive synergy corresponding to a FICI of >0.5 to ≤1; no interaction (indifference) corresponding to a FICI of >1 to ≤4; and antagonism corresponding to a FICI of >>4). The synergistic effect of the three compounds is defined as FICI ≤ 1.0 (Berenbaum, 1978; Yu et al., 1980).
[0095] [Examples] As shown in the following examples, BRAFMT MSS cell lines exhibit increased sensitivity to BOLD-100, an inducer of DNA replication stress and UPR activation. BOLD-100 results in a rapid increase in ROS and activation of ATR / CHK DNA damage signaling kinase in BRAFMT CRC cells. ATR inhibition, when combined with BOLD-100, significantly reduces cell viability and increases cell death in BRAFMT CRCs.
[0096] [Example 1] Endoplasmic reticulum protein response (UPR) and DNA repair are the major deregulated pathways in the CMS1 / BRAFMT subgroup, which exhibits the worst outcomes.
[0097] Data analysis of the GSE59857 dataset: Heatmaps were created using the CMScaller application with R Studio version 1.3.959. The CMScaller application provides a consensus molecular subtype (CMS) classification of preclinical models of clinical reproductive cells (see Guinney et al., Nat Med. 2015 Nov;21(11):1350-6; CMS1 “microsatellite instability immune”, hypermutation, microsatellite instability and strong immune activation; CMS2 “canonical”, epithelial, marked WNT and MYC signaling activation; CMS3 “metabolic”, epithelial and obvious metabolic dysregulation; and CMS4 “mesenchymal”, marked transforming growth factor β activation, stromal infiltration and angiogenesis).
[0098] Materials: A panel of isogenic and heterogenic V600E BRAFMT and BRAFWT cells was used. BOLD-100, a ruthenium-based small molecule inhibitor, was obtained from BOLD Therapeutics. An FDA-approved compound library was used.
[0099] Methods: Cell Title Glo, annexin V / PI high content screening, flow cytometry, Western blotting, caspase 8, 3 / 7 activity, ROS-GloaH2O2, and RNAi assays were used. RNA sequencing and bioinformatics were performed on BRAFMT / WTCRC cells treated with BOLD-100 using the Illumina Novoseq platform and Reactome Pathway Analysis.
[0100] As shown in Figure 1, the GSE59857 dataset was embedded in the platform during its creation, and therefore, heatmaps were created from this Log2-normalized dataset using the "Biobase" and "limma" packages in R for the CMScaller implementation. The "subcamera" function within the CMScaller program is used to visualize the heatmaps created after gene set analysis and stratification by CMS profiling. These heatmaps then contain CMS profiles along the X-axis and pathway names by Hallmark along the Y-axis.
[0101] [Example 2] BRAFMT and MSS CRC cells are sensitive to treatment with BOLD-100. As illustrated in Figure 2, BRAFMT and CMS1 CRC cells exhibit increased sensitivity to treatment with BOLD-100. Top: A. BRAFMT V600E HT-29 cells were treated with BOLD-100 for the indicated time, and GRP78, CHOP, and PARP levels were determined by Western blotting (WB). B. HT-29 cells were treated with BOLD-100 for the indicated time, and HSPA5, ATF4, and DDIT3 mRNA levels were quantified using RT-PCR. Raw values were normalized for the expression of housekeeping genes ACTB and GAPDH and analyzed using the ΔΔCT method. Bottom: A. CRC cells were treated with increasing concentrations of BOLD-100, and cell viability was determined using the CellTitle-Glo® assay. IC was performed using the Prism software package. 50 The following calculations were performed. B.CRC cells were treated with BOLD-100 for 48 hours. Apoptosis was evaluated by high-content screening using annexin V / propidium iodide (PI) staining. The graph shows the percentage of positively stained cells after treatment with 100 μM BOLD-100. The mean values from three independent experiments are shown.
[0102] [Example 3] Oncogenic BRAF is a determinant of the response to BOLD-100 treatment. As shown in Figure 3, oncogenic BRAF is a determinant of the response to BOLD-100 treatment. A. Upper: Isogenic BRAFMT and BRAFWT CRC cells were treated with increasing concentrations of BOLD-100 for 72 hours, and cell viability was determined using the CellTitre-Glo® assay. IC50 was calculated using the Prism software package. Lower: PARP in CRC cells treated with BOLD-100 for 48 hours. B. Expression of BRAF, pMEK1 / 2, MEK1 / 2, ATF4, CHOP, PARP and cleaved C3 in VT1 CRC cells transiently transfected with 1 μg of BRAFV600E expression construct for 12 hours, followed by treatment with BOLD-100 for 24 hours. C. Left: CRC cells were co-treated with vemurafenib and BOLD-100 for 48 hours, and PARP, GRP78, CHOP, pMEK1 / 2, MEK1 / 2 levels were determined by WB. Right: CRC cells were co-treated for 72 hours with no drug (control), vemurafenib, BOLD-100, or vemurafenib in combination with BOLD-100. CI values were calculated using the Chou and Talalay method, where CI<0.3, 0.3<CI<0.7, 0.7<CI<0.85, 0.85<CI<1, CI=1, and CI>1 indicate very strong synergism, strong synergism, moderate synergism, slight synergism, additive interaction, and antagonism, respectively.
[0103] [Example 4] BOLD-100-induced cell death is caspase 8 dependent As shown in Figure 4, BOLD-100-induced cell death in this model is caspase-8 dependent. A. Positive hits from primary siRNA screening against 178 target TSGs. sRNAs were treated with BOLD-100 for 24 hours, followed by treatment with BOLD-100 for 48 hours. 46 targets were identified, resulting in either increased sensitivity or resistance to BOLD-100 (based on robust z-score ±1). B. Positive hits from secondary siRNA screening using two additional siRNA sequences against 46 targets. C. CRC cells were pre-incubated for 3 hours with DMSO or 20 μM of the pan-caspase inhibitor z-VAD-FMK, followed by treatment with BOLD-100 for 48 hours, and then apoptosis was assessed by WB analysis for PARP (top) and caspase-3 / 7 activity assays (bottom). D. Top: CRC cells were transfected with 10 nM C8, C9, or C8 / C9 siRNA for 24 hours, followed by treatment with BOLD-100 for 48 hours. Apoptosis was evaluated by WB analysis for PARP (left) and caspase-3 / 7 activity (right). Bottom: Paired CRISPR HCT116 C8WT and HCT116 C8null cells were treated with BOLD-100 for 48 hours. Apoptosis was determined by WB analysis for PARP (left) and caspase-3 / 7 activity levels (right).
[0104] [Example 5] BOLD-100 treatment leads to deregulation of the DNA damage repair pathway in BRAFMT CRCs. As shown in Figure 5, BOLD-100 treatment results in activation of DNA damage repair pathways in BRAFMT CRCs: A. Heatmaps of significantly downregulated and upregulated genes after 3 and 24 hours of BOLD-100 treatment in isogeneic BRAFMT and WTCRC cells. B. Metacore pathway analysis of significantly downregulated and upregulated genes in the BRAFMT VACO432 cell line.
[0105] [Example 6] ATR inhibition significantly increases the response to BOLD-100 treatment As shown in Figure 6, ATR inhibition significantly increases the response to BOLD-100 treatment in BRAFMT CRC cells. The FDA approved a drug screening that targets significant pathways that are dysregulated after BOLD-100 treatment in BRAFMT CRC. BRAFMT HT-29 (A) and VACO432 (B) cells were treated with 60 FDA-approved drugs alone or in combination with BOLD-100 at the BOLD-100, IC 10 , IC 20 , IC 30 doses for 72 hours, and cell viability was determined using the CellTitre-Glo® assay. Robust z-scores were calculated for the combination treatments and normalized to the effect of 50 μM BOLD-100. Combinations with an r-Z score of <-1 were considered to increase sensitivity to BOLD-100 treatment. Cell viability of the combined BOLD-100 / AZD6738 treatment was graphed using GraphPad Prism 8.0. C. Clonogenic survival assay in BRAFMT LIM2405, VACO432 and RKO CRC cells after 14 days of co-treatment with BOLD-100 and AZD6738. Survival was graphed using GraphPad Prism 8.0.
[0106] [Example 7] The ATR small molecule inhibitors AZD6738, M4344 and berzosertib increase cell death after BOLD-100 treatment in BRAFMT CRC As shown in Figure 7, ATR SMI AZD6738, M4344, and belzocertib increase cell death in BRAFMT CRCs after BOLD-100 treatment. HT-29 and VACO432 CRC cells were co-treated with BOLD-100 and ATRi AZD6738, M4344, or belzocertib for 48 hours, and apoptosis was evaluated using WB analysis for PARP and cleavage caspase-3 (A) and caspase 3 / 7 activity assays (B). C. BRAFMT CRC cells VACO432, COLO205, and LIM2405 were co-treated with BOLD-100 and ATRi AZD6738, M4344, or belzocertib for 48 hours, and apoptosis was evaluated by PI flow cytometry.
[0107] [Example 8] BOLD-100 induces ROS-dependent ATR / CHK1 kinase activation and cell death in BRAFMT CRC cells. As shown in Figure 8, BOLD-100 induces ROS-dependent ATR / CHK1 kinase activation and cell death in BRAFMT CRC cells. A. BRAFMT CRC cells were treated with BOLD-100 for the indicated time, and ATR / KAP1 / CKH1 / CHK2 expression / activity was measured by WB. B. CRC cells were co-treated with BOLD-100 and AZD6738 for 48 hours, and phosphorylation / expression of ATR / KAP1 and downstream kinases was measured. C. CRC cells were treated with BOLD-100 for the indicated time, and ROS production was measured using the ROS-Glo(trademark) H2O2 assay. D. and E. WB and caspase 3 / 7 activity in cells pre-treated with NAC for 3 hours, followed by a further 24 hours of treatment with BOLD-100.
[0108] [Example 9] BOLD-100 is most effective in processing difficult CMS1 and CMS4 CRCs. In this example, 20 colon cancer cell lines were treated with BOLD-100 at increasing concentrations for 72 hours, and their viability was measured by a standard Cell Titer-Glo (CTG) luminescent cell viability assay. The IC of each cell line was obtained from dose-response curves using the Prism software package. 50 The following was determined: Colon cancer cell lines were classified into different subtypes based on the consensus molecular subtype (CMS) classification of the CRC preclinical model. As shown in Figure 9, the CMS1 and CMS4 subtypes were shown to be the most responsive to BOLD-100 monotherapy treatment. From minimum to maximum IC 50 The distribution is shown with two-directional bars, and the median is shown with a horizontal bar. CMS1 and CMS4 subtypes with BRAF mutations have the worst overall survival and response rates, demonstrating that BOLD-100 is remarkably effective in treating difficult-to-treat subtypes of colorectal cancer.
[0109] [Example 10] ATR inhibition significantly increases the response to BOLD-100 treatment in multiple myeloma. Myeloma is a lymphoid malignancy primarily involving plasma cells residing in the bone marrow, although malignant plasma cells can also be found in peripheral blood, soft tissues, and organs. Therefore, myeloma is a plasma cell disorder that can be distinguished by its site of involvement: multiple myeloma involves several different areas, plasmacytoma involves only one site, focal myeloma involves adjacent sites, and extramedullary myeloma involves tissues other than the bone marrow. Thus, as used herein, the term “myeloma” refers to the range of diseases recognized in the art. Within this range, relapsed MM is generally considered a recurrence of the disease after a previous response, typically based on objective clinical criteria, while relapsed / refractory MM (RRMM) is generally defined as a disease that becomes unresponsive or progressive within 60 days of therapy or last treatment in patients who achieved a minimum response (MR) or better with previous therapy. Managing RRMM presents specific challenges.
[0110] In this example, multiple myeloma cell lines were treated with escalating doses of BOLD-100 in combination with the ATR inhibitor BAY 1895344 for either 24 hours (Figure 10(A) left panel) or 48 hours (Figure 10(A) right panel), and cell viability was measured by a standard Cell Titer-Glo (CTG) luminescent cell viability assay. Figure 10(A) shows the response in the multiple myeloma cell line MM.1S, while Figure 10(B) shows the response in the multiple myeloma cell line KMS18. The bar graphs represent the number of viable cells in the assay using MM.1S cells compared to the vehicle control. The scatter plots represent the degree of synergistic effect between drug combinations at different dose levels. In the scatter plots, compound interactions were calculated as combination indices (CIs) from multiple drug effect analysis performed by the central equation principle, following the methodology described by Chou and Talalay, using Compusyn software, version 1.0 (see Chou TC. "Drug combination studies and their synergy quantification using the Chou-Talalay method." Cancer Res. 2010 Jan 15;70(2):440-6). CI values are one way to indicate the synergistic, additive, or antagonistic behavior of drug combinations. Using this method, CI < 1, = 1, and > 1 indicate synergistic, additive, and antagonistic effects, respectively. A synergistic interaction between two drugs to reduce cell viability was observed.
[0111] References Venderbosch S, Nagtegaal ID, Maughan TS, et al. Clin Cancer Res.2014;20(20):5322-30. Lochhead P, Kuchiba A, Imamura Y, et al.J Natl Cancer Inst.2013;105(15):1151-6. Kopetz,S.et al.Encorafenib,Binimetinib,and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.N Engl J Med.381,1632-1643(2019). Guinney,J.et al.The consensus molecular subtypes of colorectal cancer.Nat Med.21,1350-1356(2015). Medico,E.et al.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.Nature communications.6,7002(2015). Burris,H.A.et al.Safety and activity of IT-139,a ruthenium-based compound,in patients with advanced solid tumours:a first-in-human,open-label,dose-escalation phase I study with expansion cohort.ESMO open.1,e000154(2016). While various embodiments of the present invention are disclosed herein, many adaptations and modifications can be made within the scope of the invention according to the common general knowledge of those skilled in the art. Such modifications include the substitution of known equivalents of any aspect of the invention to achieve substantially the same results in substantially the same manner. Terms such as “exemplary” or “illustrated” are used herein to mean “serving as an example, case, or illustration.” Embodiments described herein as “exemplary” or “illustrated” should not be construed accordingly as necessarily preferable or advantageous to other embodiments, and all such embodiments are independent embodiments. Unless otherwise specified, numerical ranges include the number defining the range, and numerical values are always approximations to a given decimal. The word “including,” is used herein as an open-ended term substantially equivalent to the phrase “including, but not limited to,” and the word “including” has the corresponding meaning. Where used herein, the singular forms “a,” “an,” and “the” include plural referents unless otherwise explicitly indicated in the context. Thus, for example, a reference to “thing” includes two or more such things. The references made herein do not constitute an admission that such references are prior art of the present invention. Any (one or more) prior art and publications, including but not limited to patents and patent applications cited herein, and all documents cited in such documents and publications, are incorporated herein by reference as if each individual publication were specifically and individually indicated and described herein in its entirety. The present invention includes substantially all embodiments and variations described herein with reference to the examples and drawings.
[0112] In some embodiments, the present invention excludes steps involving medical or surgical treatment. In one embodiment, the present invention provides the following. [Item 1] A method for treating cancer in human patients requiring the treatment thereof, comprising administering an effective amount of trans-[tetrachloridobis(1H-indazole)rutheniumate sodium(III)] and an effective amount of an inhibitor of telangiectatic ataxia mutation and Rad3-related protein kinase (ATRi). [Item 2] The method according to item 1, wherein the effective amount of trans-[tetrachloridobis(1H-indazole)ruthenate sodium(III)] and the effective amount of ATRi are synergistically effective in treating the cancer. [Item 3] The method according to item 1 or 2, wherein the cancer is resistant to treatment with trans-[tetrachloridobis(1H-indazole)rutheniumate sodium(III)] alone, or resistant to treatment with ATRi alone, or resistant to another chemotherapeutic agent or chemotherapy regimen. [Item 4] The method according to any one of items 1 to 3, wherein the cancer is colorectal cancer (CRC) or myeloma. [Item 5] The method according to item 4, wherein the CRC is adenocarcinoma or the myeloma is multiple myeloma. [Item 6] The cancer is characterized by a BRAF mutation (BRAFMT) and is a method according to any one of items 1 to 5. [Item 7] The cancer is characterized by microsatellite stability (MSS) as described in any one of items 1 to 6. [Item 8] A method for treating cancer in a human patient requiring the use thereof, comprising administering an effective amount of trans-[tetrachloridobis(1H-indazole)rutheniumate sodium(III)], wherein the cancer is colorectal cancer (CRC) characterized by a BRAF mutation (BRAFMT) or consensus molecule subtype (CMS) CMS1 or CMS4. [Item 9] The method described in item 8, wherein the BRAFMT CRC is an adenocarcinoma. [Item 10] The method according to item 8 or 9, wherein the BRAFMT CRC is characterized by microsatellite stability (MSS). [Item 11] The method according to any one of items 8 to 10, wherein trans-[tetrachloridobis(1H-indazole)ruthenium sodium(III)] is administered in combination with an effective amount of a telangiectatic ataxia mutation inhibitor and Rad3-related protein kinase (ATRi). [Item 12] The method according to item 11, wherein the effective amount of trans-[tetrachloridobis(1H-indazole)ruthenate sodium(III)] and the effective amount of ATRi are synergistically effective in treating the cancer. [Item 13] The method according to item 11 or 12, wherein the cancer is resistant to treatment with trans-[tetrachloridobis(1H-indazole)rutheniumate sodium(III)] alone, or resistant to treatment with ATRi alone, or resistant to another chemotherapeutic agent or chemotherapy regimen. [Item 14] The method according to any one of items 1 to 7 or 11 to 13, wherein the trans-[tetrachloridobis(1H-indazole)ruthenate sodium(III)] and the ATRi are administered sequentially in any order. [Item 15] The method according to any one of items 1 to 7 or 11 to 13, wherein the trans-[tetrachloridobis(1H-indazole)rutheniumate sodium(III)] and the ATRi are administered together, in a co-formulation, or separately. [Item 16] The following genes: ATR (ATR serine / threonine kinase); CYB561D2 (cytochrome b561 family, member D2); DLC1 (DLC1 Rho GTPase activating protein); DMBT1 (deletion in malignant brain tumor 1); E2F1 (E2F transcription factor 1); GLTSCR2 (glioma tumor suppressor candidate region gene 2); GPS1 (G protein pathway inhibitor 1); HSP90B1 (heat shock protein 90kDa beta (Grp94), member 1); JUNB (jun B proto-oncogene); KSR2 (ras2 kinase suppressor); LZTS2 (leucine zipper, putative tumor suppressor 2); MEN1 (multiple endocrine neoplasm I); MTUS1 (microtubule-associated tumor suppressor 1); NF1 (neurofibromin 1); NPRL2 (nitrogen permease regulator-like 2 (budding yeast (S. cerevisiae)); OVCA2 (ovarian tumor suppressor candidate 2); RAD54L (RAD54-like (budding yeast (S. cerevisiae)); RSPH14 (radial spoke head 14 homolog (Cra The method according to any one of items 1 to 15, further comprising administering an inhibitor of the expression of one or more of the following: Chlamydomonas; SACM1L (actin mutant 1-like (yeast) SAC1 suppressor); SUFU (fusion homolog (Drosophila) suppressor); TGFBR2 (transforming growth factor, beta receptor II (70 / 80 kDa)); TNFSF10 (tumor necrosis factor (ligand) superfamily, member 10); WTAP (Wilms tumor 1-associated protein). [Item 17] The method according to item 16, wherein the expression inhibitor is siRNA. [Item 18] The following genes: ATR (ATR serine / threonine kinase); CYB561D2 (cytochrome b561 family, member D2); DLC1 (DLC1 Rho GTPase activating protein); DMBT1 (deletion in malignant brain tumor 1); E2F1 (E2F transcription factor 1); GLTSCR2 (glioma tumor suppressor candidate region gene 2); GPS1 (G protein pathway inhibitor 1); HSP90B1 (heat shock protein 90kDa beta (Grp94), member 1); JUNB (jun B proto-oncogene); KSR2 (ras2 kinase suppressor); LZTS2 (leucine zipper, putative tumor suppressor 2); MEN1 (multiple endocrine neoplasm I); MTUS1 (microtubule-associated tumor suppressor 1); NF1 (neurofibromin 1); NPRL2 (nitrogen permease regulator-like 2 (budding yeast (S. cerevisiae)); OVCA2 (ovarian tumor suppressor candidate 2); RAD54L (RAD54-like (budding yeast (S.cerevisiae); RSPH14 (Radial spoke head 14 homolog (Chlamydomonas)); SACM1L (Actin mutation 1-like (yeast) SAC1 suppressor); SUFU (Fusion homolog (Drosophila) suppressor); TGFBR2 (Transforming growth factor, beta receptor II (70 / 80kDa)); TNFSF10 (Tumor necrosis factor (ligand) superfamily, member 10); W TAP (Wilms tumor 1-associated protein); APC (adenomatous polyposis of the colon); BLM (Bloom syndrome, RecQ helicase-like); CASP8 (caspase 8, apoptosis-related cysteine peptidase); CDKN1A (cyclin-dependent kinase inhibitor 1A (p21, Cip1)); ERAP1 (endoplasmic reticulum aminopeptidase 1); ERCC1 (extraction and repair cross-complementary group 1); FANCG (Fanconi anemia, complementary group G); GLTSCR1 (glioma). The method according to any one of items 1 to 17, further comprising assaying a sample from the patient for mutations in one or more of the following: candidate tumor suppressor region genes 1); PALB2 (partner and localizer of BRCA2); PTTG1IP (pituitary tumor transformation 1 interaction protein); PTTG2 (pituitary tumor transformation 2); RB1 (retinoblastoma 1); RB1CC1 (RB1-inducible coil-like coil 1); RBBP7 (retinoblastoma-binding protein 7); TP53 (tumor protein p53); TP53I11 (tumor protein p53-inducible protein 11); TSG101 (tumor sensitivity 101); TUSC3 (candidate tumor suppressor 3); VBP1 (von Hippel-Lindau binding protein 1); WT1 (Wilms tumor 1); WWOX (WW domain containing oxidoreductase); XPA (xeroderma pigmentosum, complement A); and / or ZNF280B (zinc finger protein 280B).
Claims
1. A composition for treating cancer in human patients in need thereof, comprising an effective amount of trans-[tetrachloridobis(1H-indazole)rutheniumate sodium (III)] and an effective amount of an inhibitor of telangiectatic ataxia mutation and Rad3-related protein kinase (ATRi), wherein the ATRi is selected from the group consisting of AZD6738, M4344, belzocertib and BAY 1895344.
2. The composition according to claim 1, wherein the effective amount of trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)] and the effective amount of ATRI are synergistically effective for treating the cancer.
3. The composition according to claim 1 or 2, wherein the cancer is resistant to treatment with trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)] alone, or resistant to treatment with ATRI alone, or resistant to another chemotherapeutic agent or chemotherapy regimen.
4. The composition according to any one of claims 1 to 3, wherein the cancer is colorectal cancer (CRC) or myeloma.
5. The composition according to claim 4, wherein the CRC is adenocarcinoma or the myeloma is multiple myeloma.
6. The composition according to any one of claims 1 to 5, wherein the cancer is characterized by a BRAF mutation (BRAFMT).
7. The composition according to any one of claims 1 to 6, wherein the cancer is characterized by microsatellite stability (MSS).
8. A composition for treating cancer in a human patient requiring the treatment thereof, comprising an effective amount of trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)], wherein the cancer is colorectal cancer (CRC) characterized by a BRAF mutation (BRAFMT) or consensus molecule subtype (CMS) CMS1 or CMS4, A composition comprising the trans-[tetrachloridobis(1H-indazole)ruthenium sodium (III)] administered in combination with an effective amount of ataxia telangiectasia mutation and Rad3-related protein kinase inhibitor (ATRi), wherein the ATRi is selected from the group consisting of AZD6738, M4344, belzocertib, and BAY 1895344.
9. The composition according to claim 8, wherein the effective amount of trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)] and the effective amount of ATRI are synergistically effective for treating the cancer.
10. The composition according to claim 8 or 9, wherein the cancer is resistant to treatment with trans-[tetrachloridobis(1H-indazole)rutheniumate sodium (III)] alone, or resistant to treatment with ATRI alone, or resistant to another chemotherapeutic agent or chemotherapy regimen.
11. The composition according to any one of claims 1 to 10, wherein the trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)] and the ATRI are administered sequentially in any order.
12. The composition according to any one of claims 1 to 10, wherein the trans-[tetrachloridobis(1H-indazole)ruthenate sodium (III)] and ATRI are administered together, in a co-formulation, or separately.
13. The following genes: ATR (ATR serine / threonine kinase); CYB561D2 (cytochrome b561 family, member D2); DLC1 (DLC1 Rho GTPase activating protein); DMBT1 (deletion in malignant brain tumor 1); E2F1 (E2F transcription factor 1); GLTSCR2 (glioma tumor suppressor candidate region gene 2); GPS1 (G protein pathway inhibitor 1); HSP90B1 (heat shock protein 90kDa beta (Grp94), member 1); JUNB (jun B proto-oncogene); KSR2 (ras2 kinase suppressor); LZTS2 (leucine zipper, putative tumor suppressor 2); MEN1 (multiple endocrine neoplasm I); MTUS1 (microtubule-associated tumor suppressor 1); NF1 (neurofibromin 1); NPRL2 (nitrogen permease regulator-like 2 (budding yeast (S. cerevisiae)); OVCA2 (ovarian tumor suppressor candidate 2); RAD54L (RAD54-like (budding yeast (S. cerevisiae)); RSPH14 (radial spoke head 14 homolog (Chlamydia) The composition according to any one of claims 1 to 12, to be used in combination with an inhibitor of the expression of one or more of the following: Chlamydomonas; SACM1L (actin mutant 1-like (yeast) SAC1 suppressor); SUFU (fusion homolog (Drosophila) suppressor); TGFBR2 (transforming growth factor, beta receptor II (70 / 80 kDa)); TNFSF10 (tumor necrosis factor (ligand) superfamily, member 10); WTAP (Wilms tumor 1-related protein).
14. The composition according to claim 13, wherein the expression inhibitor is siRNA.
15. The following genes: ATR (ATR serine / threonine kinase); CYB561D2 (cytochrome b561 family, member D2); DLC1 (DLC1 Rho GTPase activating protein); DMBT1 (deletion in malignant brain tumor 1); E2F1 (E2F transcription factor 1); GLTSCR2 (glioma tumor suppressor candidate region gene 2); GPS1 (G protein pathway inhibitor 1); HSP90B1 (heat shock protein 90kDa beta (Grp94), member 1); JUNB (jun B proto-oncogene); KSR2 (ras2 kinase suppressor); LZTS2 (leucine zipper, putative tumor suppressor 2); MEN1 (multiple endocrine neoplasm I); MTUS1 (microtubule-associated tumor suppressor 1); NF1 (neurofibromin 1); NPRL2 (nitrogen permease regulator-like 2 (budding yeast (S. cerevisiae)); OVCA2 (ovarian tumor suppressor candidate 2); RAD54L (RAD54-like (budding yeast) (S. cerevisiae); RSPH14 (Radial spoke head 14 homolog (Chlamydomonas)); SACM1L (Actin mutation 1-like (yeast) SAC1 suppressor); SUFU (Fusion homolog (Drosophila) suppressor); TGFBR2 (Transforming growth factor, beta receptor II (70 / 80 kDa)); TNFSF10 (Tumor necrosis factor (ligand) super Family, Member 10); WTAP (Wilms tumor 1-related protein); APC (adenomatous polyposis of the colon); BLM (Bloom syndrome, RecQ helicase-like); CASP8 (caspase 8, apoptosis-related cysteine peptidase); CDKN1A (cyclin-dependent kinase inhibitor 1A (p21, Cip1)); ERAP1 (endoplasmic reticulum aminopeptidase 1); ERCC1 (extraction and repair cross-complementarity group 1); FANCG ( Fanconi anemia (complementary group G); GLTSCR1 (candidate region gene for glioma tumor suppressor 1); PALB2 (partner and localizer of BRCA2); PTTG1IP (pituitary tumor transformation 1 interaction protein); PTTG2 (pituitary tumor transformation 2); RB1 (retinoblastoma 1); RB1CC1 (RB1-inducible coil-like coil 1); RBBP7 (retinoblastoma-binding protein 7); TP53 (tumor protein p53);The composition according to any one of claims 1 to 14, to be used in combination with assaying a sample from the patient for mutations in one or more of the following: TP53I11 (tumor protein p53-inducible protein 11); TSG101 (tumor sensitivity 101); TUSC3 (candidate tumor suppressor 3); VBP1 (von Hippel-Lindau binding protein 1); WT1 (Wilms tumor 1); WWOX (WW domain containing oxidoreductase); XPA (xeroderma pigmentosum, complementary group A); and / or ZNF280B (zinc finger protein 280B).
Citation Information
Patent Citations
Methods for treating intractable cancers
JP2013531064A
Use of chronic treatment with ATR inhibitors to sensitize cancer cells to PARP inhibitors
US20190365745A1
Treating cancer using inhibitors of ataxia-telangiectasia mutated and RAD3-related (ATR)
WO2016112374A2
Inhibitors of ataxia-telangiectasia mutated and RAD3-related protein kinase (ATR) for use in methods of treating cancer
WO2017118734A1
Ataxia telengiectasia and RAD3-related (ATR) inhibitors and methods of their use
WO2017180723A1
